Oral anticoagulants for stroke prevention in atrial fibrillation

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)
356 Downloads (Pure)


The availability of 4 non–vitamin K oral anticoagulants (NOACs), that is, dabigatran, rivaroxaban, apixaban, and edoxaban, has changed the landscape of stroke prevention in patients with atrial fibrillation. This review article provides an overview of the 4 phase III studies that have compared these NOACs, examining major outcomes of efficacy and safety. A range of practical questions relating to the NOACs have emerged, including topics such as patient selection, treating patients with renal impairment, treating elderly patients, and combining anticoagulant therapy with antiplatelet drugs. We also address the interaction of various patient characteristics with the treatments and suggest the features can assist the physician in the choice of a particular NOAC for a particular patient(s).
Original languageEnglish
Pages (from-to)319-344
JournalCurrent Problems in Cardiology
Issue number9
Early online date17 Jul 2014
Publication statusPublished - 1 Sept 2014


Dive into the research topics of 'Oral anticoagulants for stroke prevention in atrial fibrillation'. Together they form a unique fingerprint.

Cite this